BioCentury
DATA GRAPHICS | Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

January 16, 2021 2:47 AM UTC

As Arcus becomes the second company to report clinical data for a CD73 inhibitor in pancreatic cancer behind front-runner AstraZeneca, at least six more teams have early-stage clinical programs targeting the immuno-metabolism modulating receptor.

An interim readout from the Phase I/Ib ARC-8 trial showed that a combo including the small molecule CD73 inhibitor AB680 from Arcus Biosciences Inc. (NASDAQ:RCUS) led to an overall response rate of 41%, with seven partial responses among 17 evaluable patients with metastatic pancreatic ductal adenocarcinoma. One patient converted to a complete response after the Dec. 9, 2020, efficacy data cut-off...